X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA SANOFI INDIA ALEMBIC PHARMA/
SANOFI INDIA
 
P/E (TTM) x 28.9 33.6 86.0% View Chart
P/BV x 6.6 6.4 103.0% View Chart
Dividend Yield % 0.7 1.4 50.7%  

Financials

 ALEMBIC PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
SANOFI INDIA
Dec-16
ALEMBIC PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs7924,560 17.4%   
Low Rs4434,400 10.1%   
Sales per share (Unadj.) Rs167.01,028.5 16.2%  
Earnings per share (Unadj.) Rs38.2129.0 29.6%  
Cash flow per share (Unadj.) Rs42.0186.0 22.6%  
Dividends per share (Unadj.) Rs4.0068.00 5.9%  
Dividend yield (eoy) %0.61.5 42.7%  
Book value per share (Unadj.) Rs84.9753.6 11.3%  
Shares outstanding (eoy) m188.5223.03 818.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.74.4 84.9%   
Avg P/E ratio x16.234.7 46.6%  
P/CF ratio (eoy) x14.724.1 61.0%  
Price / Book Value ratio x7.35.9 122.3%  
Dividend payout %10.552.7 19.9%   
Avg Mkt Cap Rs m116,383103,174 112.8%   
No. of employees `000NA3.6 0.0%   
Total wages/salary Rs m4,2143,592 117.3%   
Avg. sales/employee Rs ThNM6,537.7-  
Avg. wages/employee Rs ThNM991.4-  
Avg. net profit/employee Rs ThNM819.8-  
INCOME DATA
Net Sales Rs m31,48723,686 132.9%  
Other income Rs m55708 7.8%   
Total revenues Rs m31,54224,394 129.3%   
Gross profit Rs m10,0605,281 190.5%  
Depreciation Rs m7221,313 55.0%   
Interest Rs m3715 245.3%   
Profit before tax Rs m9,3564,661 200.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1601,691 127.7%   
Profit after tax Rs m7,1942,970 242.2%  
Gross profit margin %31.922.3 143.3%  
Effective tax rate %23.136.3 63.6%   
Net profit margin %22.812.5 182.2%  
BALANCE SHEET DATA
Current assets Rs m15,06615,673 96.1%   
Current liabilities Rs m7,6746,678 114.9%   
Net working cap to sales %23.538.0 61.8%  
Current ratio x2.02.3 83.6%  
Inventory Days Days6776 88.1%  
Debtors Days Days4122 182.1%  
Net fixed assets Rs m8,2378,098 101.7%   
Share capital Rs m377230 163.7%   
"Free" reserves Rs m15,41617,088 90.2%   
Net worth Rs m16,00517,356 92.2%   
Long term debt Rs m00-   
Total assets Rs m24,59425,400 96.8%  
Interest coverage x255.2311.7 81.9%   
Debt to equity ratio x00-  
Sales to assets ratio x1.30.9 137.3%   
Return on assets %29.411.8 250.2%  
Return on equity %44.917.1 262.7%  
Return on capital %58.726.9 217.8%  
Exports to sales %55.724.5 227.6%   
Imports to sales %10.428.0 37.3%   
Exports (fob) Rs m17,5515,801 302.5%   
Imports (cif) Rs m3,2836,627 49.5%   
Fx inflow Rs m17,8117,145 249.3%   
Fx outflow Rs m5,3186,846 77.7%   
Net fx Rs m12,493299 4,178.1%   
CASH FLOW
From Operations Rs m9,3043,226 288.4%  
From Investments Rs m-3,105-1,555 199.7%  
From Financial Activity Rs m-1,959-1,818 107.8%  
Net Cashflow Rs m4,240-147 -2,884.4%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 2.9 14.4 20.1%  
FIIs % 9.1 14.6 62.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.5 132.4%  
Shareholders   49,328 15,184 324.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   PANACEA BIOTECH  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 22, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - BIOCON LTD COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS